Studies found that administration of anti-PD-1/PD-L1 blocking antibodies (called pembrolizumab) is effective in treating recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) [7–9]. Here, CD274 is linked to head and neck squamous cell carcinoma.